EBITDA adjusted amounted to EUR 1.47B, exceeding guidance, with a margin of 22.4%. Reported net profit totaled EUR 59M in 2023. Thomas Glanzmann, Grifols’ Executive Chairman and CEO commented: “We delivered fully on our commitments in a record 2023 marked by focus on governance and progressively stronger operational and financial performance. From a re-energized plasma business to completing innovation milestones to the strategic alliance with Haier Group in support of deleveraging, our actions have built a strong momentum and set us up for sustainable profitable growth into 2024 and beyond.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GRFS:
- GRFS Earnings this Week: How Will it Perform?
- Grifols price target raised to EUR 19.40 from EUR 18.60 at Berenberg
- Grifols announces FC from Biotest met primary endpoint
- Grifols announces positive topline phase 3 fibrinogen clinical trial results
- Grifols names Nacho Abia CEO, transitions for CCO, COO
